Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gogoro Inc (GGR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Gogoro IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Gogoro Inc vs Neurocrine Biosciences Inc — how do they compare? Gogoro Inc trades at $2.51 (market cap $52.19M), while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 315.4× Gogoro Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.

GGRNBIX
Market Cap
$52.19M$16.46B
Sector
TechnologyHealth
52-Week High
$7.50$185.50
52-Week Low
$2.55$123.10
Enterprise Value
$354.63M$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gogoro Inc

GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).

The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gogoro Inc

Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.

Read more on GGR

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX